Abstract
The drug of choice for tuberculosis (TB) preventive therapy is isoniazid (INH). Preventive therapy can reduce TB incidence up to 60 %. In those infected with HIV, where the risk of progression from infection to active TB disease is 20–37 times higher, INH has proven effective in preventing TB disease. The priority populations for preventive therapy are the HIV positive and children younger than 5 years old who have household close contact with smear-positive TB patients. The main challenges with preventive therapy are adverse drug reactions and compliance issues. TB preventive therapy has become an important TB control strategy in many high-income countries. The high cost, poor acceptability, and difficulties in treatment management limit the application of preventive therapy in low-income countries.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Akolo, C., Adetifa, I., Shepperd, S., & Volmink, J. (2010). Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database of Systematic Reviews, 1, CD000171.
American Thoracic Society. (1986). American Thoracic Society. Medical Section of the American Lung Association: Treatment of tuberculosis and tuberculosis infection in adults and children. The American Review of Respiratory Disease, 134(2), 355–363.
American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America. (2003). American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of tuberculosis. American Journal of Respiratory and Critical Care Medicine, 167(4), 603–662.
Camins, B. C., Bock, N., Watkins, D. L., & Blumberg, H. M. (1996). Acceptance of isoniazid preventive therapy by health care workers after tuberculin skin test conversion. JAMA, 275(13), 1013–1015.
Centers for Disease Control and Prevention (CDC). (1996). The role of BCG vaccine in the prevention and control of tuberculosis in the United States. A joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices. Morbidity and Mortality Weekly Report, 45(RR-4), 1–18.
Centers for Disease Control and Prevention (CDC). (2001). Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection—New York and Georgia, 2000. Morbidity and Mortality Weekly Report, 50(15), 289–291.
Centers for Disease Control and Prevention (CDC). (2010). Latent tuberculosis infection: A guide for primary health care providers. Atlanta: Centers for Disease Control and Prevention. Updated version. Retrieved Mar 4, 2015, from http://www.cdc.gov/tb/publications/ltbi/pdf/targetedltbi.pdf
Cohn, D. L., O’Brien, R. J., Geiter, L. J., Gordin, F. M., Hershfield, E., Horsburgh, C. R., et al. (2000). Targeted tuberculin testing and treatment of latent tuberculosis infection. Morbidity and Mortality Weekly Report, 49(6), 1–54.
Comstock, G. W. (1999). How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? [Counterpoint]. The International Journal of Tuberculosis and Lung Disease, 3(10), 847–850.
Comstock, G. W., Ferebee, S. H., & Hammes, L. M. (1967). A controlled trial of community-wide isoniazid prophylaxis in Alaska. The American Review of Respiratory Disease, 95(6), 935–943.
Corbett, E. L., Watt, C. J., Walker, N., Maher, D., Williams, B. G., Raviglione, M. C., et al. (2003). The growing burden of tuberculosis: Global trends and interactions with the HIV epidemic. Archives of Internal Medicine, 163(9), 1009–1021.
Egsmose, T., Ang’Awa, J. O. W., & Poti, S. J. (1965). The use of isoniazid among household contacts of open cases of pulmonary tuberculosis. Bulletin of the World Health Organization, 33(3), 419–433.
Ena, J., & Valls, V. (2005). Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: A meta-analysis. Clinical Infectious Diseases, 40(5), 670–676.
Ferebee, S. H. (1970). Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibliotheca Tuberculosea, 26, 28–106.
Ferebee, S. H., & Mount, F. W. (1962). Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. American Review of Respiratory Disease, 85, 490–510.
Ferebee, S. H., Mount, F. W., Murray, F. J., & Livesay, V. T. (1963). A controlled trial of isoniazid prophylaxis in mental institutions. American Review of Respiratory Disease, 88, 161–175.
Gao, S. Y., Zhang, G. R., Ma, S. W., Wang, G. J., & Wang, Y. Y. (2004). Study on treatment effects of rifapentine preventing tuberculosis for positive PPD reaction. Henan Medical Research, 13(4), 347–350.
Gao, X. F., Wang, L., Liu, G. J., Wen, J., Sun, X., Xie, Y., et al. (2006). Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: A meta-analysis [Review Article]. The International Journal of Tuberculosis and Lung Disease, 10(10), 1080–1090.
Garibaldi, R. A., Drusin, R. E., Ferebee, S. H., & Gregg, M. B. (1972). Isoniazid-associated hepatitis. Report of an outbreak. The American Review of Respiratory Disease, 106(3), 357–365.
Getahun, H., Gunneberg, C., Granich, R., & Nunn, P. (2010). HIV infection—Associated tuberculosis: The epidemiology and the response. Clinical Infectious Diseases, 50(Suppl. 3), S201–S207.
Girling, D. J. (1982). Adverse effects of antituberculosis drugs. Drugs, 23(1–2), 56–74.
Goldman, A. L., & Braman, S. S. (1972). Isoniazid: A review with emphasis on adverse effects. Chest, 62(1), 71–77.
Gordin, F., Chaisson, R. E., Matts, J. P., Miller, C., de Lourdes Garcia, M., Hafner, R., et al. (2000). Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: An international randomized trial. JAMA, 283(11), 1445–1450.
Heal, G., Elwood, R. K., & FitzGerald, J. M. (1998). Acceptance and safety of directly observed versus self-administered isoniazid preventive therapy in aboriginal peoples in British Columbia. The International Journal of Tuberculosis and Lung Disease, 2(12), 979–983.
Holscher, C. G. B. (1968). Secondary chemoprophylaxis with isonicotinic acid hydrazide. Dissertation. Summary. Retrieved from http://irs.ub.rug.nl/ppn/82224621X
Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. (1992). A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. American Review of Respiratory Disease, 145(1), 36–41.
Horsburgh, C. R., Jr., & Rubin, E. J. (2011). Latent tuberculosis infection in the United States. New England Journal of Medicine, 364(15), 1441–1448.
Horsburgh, C. R., Jr., Goldberg, S., Bethel, J., Chen, S., Colson, P. W., Hirsch-Moverman, Y., et al. (2010). Latent TB infection treatment acceptance and completion in the United States and Canada. Chest, 137(2), 401–409.
Horwitz, O., Payne, P. G., & Wilbek, E. (1966). Epidemiological basis of tuberculosis eradication: 4. The isoniazid trial in Greenland. Bulletin of the World Health Organization, 35(4), 509–526.
International Union Against Tuberculosis Committee on Prophylaxis. (1982). Efficacy of various durations of isoniazid preventive therapy for tuberculosis: Five years of follow-up in the IUAT trial. Bulletin of the World Health Organization, 60(4), 555–564.
Jasmer, R. M., Snyder, D. C., Chin, D. P., Hopewell, P. C., Cuthbert, S. S., Paz, E. A., et al. (2000). Twelve months of isoniazid compared with four months of isoniazid and rifampin for persons with radiographic evidence of previous tuberculosis: An outcome and cost-effectiveness analysis. American Journal of Respiratory and Critical Care Medicine, 162(5), 1648–1652.
Konstantinos, A. (2010). Testing for tuberculosis. Australian Prescriber, 33(1), 12–18.
Kopanoff, D. E., Snider, D. E., Jr., & Caras, G. J. (1978). Isoniazid-related hepatitis: A US Public Health Service cooperative surveillance study. The American Review of Respiratory Disease, 117(6), 991–1001.
Lardizabal, A., Passannante, M., Kojakali, F., Hayden, C., & Reichman, L. B. (2006). Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest, 130(6), 1712–1717.
Lecoeur, H. F., Truffot-Pernot, C., & Grosset, J. H. (1989). Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. American Journal of Respiratory and Critical Care Medicine, 140(5), 1189–1193.
Lobue, P., & Menzies, D. (2010). Treatment of latent tuberculosis infection: An update. Respirology, 15(4), 603–622.
LoBue, P. A., & Moser, K. S. (2003). Use of isoniazid for latent tuberculosis infection in a public health clinic. American Journal of Respiratory and Critical Care Medicine, 168(4), 443–447.
Long, R., & Ellis, E. (Eds.). (2007). Canadian tuberculosis standards (6th ed.). Ottawa: Public Health Agency of Canada. Retrieved Mar 4, 2015, from http://csao.net/files/pdfs/Canadian%20Tuberculois%20Standards%202007%206th%20edition.pdf
Manabe, Y. C., & Bishai, W. R. (2000). Latent Mycobacterium tuberculosis—persistence, patience, and winning by waiting. Nature Medicine, 6(12), 1327–1329.
McNab, B. D., Marciniuk, D. D., Alvi, R. A., Tan, L., & Hoeppner, V. H. (2000). Twice weekly isoniazid and rifampin treatment of latent tuberculosis infection in Canadian plains Aborigines. American Journal of Respiratory and Critical Care Medicine, 162(3), 989–993.
Menzies, D., Dion, M. J., Rabinovitch, B., Mannix, S., Brassard, P., & Schwartzman, K. (2004). Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. American Journal of Respiratory and Critical Care Medicine, 170(4), 445–449.
Monaco, A. (1964). Antituberculous chemoprophylaxis in silicotics. Bulletin of the International Union against Tuberculosis, 35, 51–56.
Mount, F. W., & Ferebee, S. H. (1962). The effect of isoniazid prophylaxis on tuberculosis morbidity among household contacts of previously known cases of tuberculosis. American Review of Respiratory Disease, 85, 821.
Mwinga, A., Hosp, M., Godfrey-Faussett, P., Quigley, M., Mwaba, P., Mugala, B. N., et al. (1998). Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS, 12(18), 2447–2457.
Page, K. R., Sifakis, F., Montes de Oca, R., Cronin, W. A., Doherty, M. C., Federline, L., et al. (2006). Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: A retrospective study. Archives of Internal Medicine, 166(17), 1863–1870.
Pape, J. W., Jean, S. S., Ho, J. L., Hafner, A., & Johnson, W. D. (1993). Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. The Lancet, 342(8866), 268–272.
Riley, L. W. (1993). Drug resistant tuberculosis. Clinical Infectious Diseases, 17(Suppl. 2), S442–S446.
Runyon, E. H. (1965). Preventive treatment in tuberculosis: A statement by the Committee on Therapy, American Thoracic Society. American Review of Respiratory Disease, 91, 297–298.
Salpeter, S. R. (1993). Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis. Western Journal of Medicine, 159(5), 560–564.
Schechter, M., Zajdenverg, R., Falco, G., Barnes, G. L., Faulhaber, J. C., Coberly, J. S., et al. (2006). Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. American Journal of Respiratory and Critical Care Medicine, 173(8), 922–926.
Snider, D. E., Jr., & Caras, G. J. (1992). Isoniazid-associated hepatitis deaths: A review of available information. The American Review of Respiratory Disease, 145(2 Pt 1), 494–497.
Snider, D. E., Jr., Caras, G. J., & Koplan, J. P. (1986). Preventive therapy with isoniazid: Cost-effectiveness of different durations of therapy. JAMA, 255(12), 1579–1583.
Steele, M. A., Burk, R. F., & DesPrez, R. M. (1991). Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest, 99(2), 465–471.
Sterling, T. R., Bethel, J., Goldberg, S., Weinfurter, P., Yun, L., & Horsburgh, C. R. (2006). The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. American Journal of Respiratory and Critical Care Medicine, 173(8), 927–931.
Tu, D. H. (2005). TB preventive therapy. Chinese Journal of Clinical Drug Therapy, 3(2), 32–34.
Whalen, C. C., Johnson, J. L., Okwera, A., Hom, D. L., Huebner, R., Mugyenyi, P., et al. (1997). A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. New England Journal of Medicine, 337(12), 801–808.
White, M., Gournis, E., Kawamura, M., Menendez, E., & Tulsky, J. (2003). Effect of directly observed preventive therapy for latent tuberculosis infection in San Francisco. The International Journal of Tuberculosis and Lung Disease, 7(1), 30–35.
WHO. (2011). Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva: World Health Organization.
Ziakas, P. D., & Mylonakis, E. (2009). 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: A meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Clinical Infectious Diseases, 49(12), 1883–1889.
Ziv, E., Daley, C. L., & Blower, S. M. (2001). Early therapy for latent tuberculosis infection. American Journal of Epidemiology, 153(4), 381–385.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media LLC
About this chapter
Cite this chapter
Zhou, L., Liu, E. (2017). Preventive Therapy Against Tuberculosis. In: Lu, Y., Wang, L., Duanmu, H., Chanyasulkit, C., Strong, A., Zhang, H. (eds) Handbook of Global Tuberculosis Control. Springer, Boston, MA. https://doi.org/10.1007/978-1-4939-6667-7_23
Download citation
DOI: https://doi.org/10.1007/978-1-4939-6667-7_23
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4939-6665-3
Online ISBN: 978-1-4939-6667-7
eBook Packages: MedicineMedicine (R0)